Recent advances in IL‐2‐based therapies involve engineered IL‐2 variants that selectively target Tregs, providing a promising avenue for developing Treg‐based therapies in chronic inflammatory conditions like periodontitis (Ye et al. 2018). The gene discussed is IL2; the disease is periodontitis.